复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

交易中 09-09 14:27:58

17.340

+0.080

+0.46%

最高17.530	最低17.050	成交量305.60万
今开17.380	昨收17.260	日振幅2.78%
总市值461.07亿	流通市值93.80亿	总股本26.59亿
成交额5,314万	换手率0.56%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":17.34,"timestamp":1788935275729,"preClose":17.26,"halted":0,"volume":3056000,"delay":0,"changeRate":0.004634994206257143,"floatShares":540971500,"shares":2659000000,"eps":1.485519437233851,"marketStatus":"交易中","change":0.08,"latestTime":"09-09 14:27:58","open":17.38,"high":17.53,"low":17.05,"amount":53138348,"amplitude":0.02781,"askPrice":17.35,"askSize":17000,"bidPrice":17.34,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":1.4972257982793913,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788941400000},"marketStatusCode":2,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":17.26,"dividendRate":0.026284,"openAndCloseTimeList":[[1788917400000,1788926400000],[1788930000000,1788940800000]],"volumeRatio":0.766503,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":22.45,"timestamp":1788935274000,"preClose":22.75,"halted":0,"volume":10459800,"delay":0,"premium":"-33.97"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2665937379","title":"复星医药：关于控股子公司药品获临床试验批准的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937379","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665937379?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:01","pubTimestamp":1788872460,"startTime":"0","endTime":"0","summary":"9月8日，复星医药发布公告称，公司控股子公司上海复星医药产业发展有限公司近日收到国家药品监督管理局关于同意FXS5626片（原项目代号：AC-201）用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868301376.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868301376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","02196","BK0096","BK0239","BK0028","BK0060","BK1191","BK1515","BMED","IBBJ","BK0187","PSYK","BK1593","BK0183","600196","MDTX","BK0188","IBBQ","BK0012","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174822287","title":"复星医药(02196)口服TYK2/JAK1双靶点抑制剂获准在华开展II/III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1174822287","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174822287?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:45","pubTimestamp":1788860754,"startTime":"0","endTime":"0","summary":"2026年9月8日，上海复星医药（集团）股份有限公司公告称，其控股子公司上海复星医药产业发展有限公司已获国家药品监督管理局批准，允许口服小分子JAK抑制剂FXS5626片在中国境内用于治疗非节段型白癜风，开展II/III期适应性无缝设计临床试验。FXS5626为TYK2/JAK1双靶点抑制剂，复星医药集团拥有其在中国内地及港澳地区的研究、开发、生产、注册和商业化独占权利。截至公告披露日，中国境内尚无TYK2/JAK1双靶点抑制剂获批上市。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131558289","title":"复星医药(02196)公告：2025年A股期权计划预留授予名单公示期满未获异议","url":"https://stock-news.laohu8.com/highlight/detail?id=1131558289","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131558289?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:42","pubTimestamp":1788860541,"startTime":"0","endTime":"0","summary":"2026年9月8日，复星医药发布海外监管公告，披露其在上海证券交易所刊登的《关于董事会薪酬与考核委员会就2025年A股股票期权激励计划预留授予激励对象名单公示情况及核查意见说明的公告》主要内容。根据中国证监会《上市公司股权激励管理办法》及公司章程，董事会薪酬与考核委员会于2026年8月29日至9月7日在公司OA网站对本次A股期权计划的预留授予激励对象姓名及职务进行公示，为期10日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113678070","title":"复星医药回购7万股股份，总额约117.52万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113678070","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113678070?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:02","pubTimestamp":1788775323,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2026年9月7日公告，已于香港联交所场内回购普通H股股份共70,000股，约占该次回购前公司已发行股本总数的0.01%。回购价格介乎每股16.74港元至16.83港元，合计支付约1,175,230港元。公司此次回购完成后，已发行股本总数变更为540,350,000股，库藏股数量增至11,590,500股。公司确认此次回购事项符合香港联合交易所有限公司证券上市规则等相关法律法规的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复星医药回购7万股股份，总额约117.52万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315565","title":"复星医药(02196)9月7日斥资117.52万港元回购7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315565","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665315565?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:00","pubTimestamp":1788775238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2026年9月7日，该公司斥资117.52万港元回购7万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK0060","BK0183","BK0196","BK0012","600196","BK0028","BK0096","BK0175","BK0188","BK1515","BK1191","02196","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392895","title":"复星医药控股股东质押3.3亿股还债 累计质押比例超7成","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392895","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665392895?lang=zh_cn&edition=full","pubTime":"2026-09-07 14:37","pubTimestamp":1788763023,"startTime":"0","endTime":"0","summary":"中国经济网北京9月7日讯 复星医药 9月5日披露的关于股东部分股份质押的公告显示，公司于2026年9月4日接到控股股东上海复星高科技(集团)有限公司的通知，其已将所持有的公司部分A股股份办理质押手续。　　复星高科技本次质押股份数量为3.3亿股，占其所持股份数比例的34.32%，占公司股份总数比例为12.36%。质押起始日为2026年9月3日，质押到期日为2028年9月8日。　　控股股东复星高科技质押公司股份均系用于融资。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/07/20260907896860.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/07/20260907896860.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260907/32361887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","BK0183","BK0012","BK0187","600196","BK0196","02196","BK0239","BK1593","BK0175","BK0096","BK1515","BK0028","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01789","02367","BK1585","LU2488822045.USD","LU1720050803.USD","BK1191","02228","KURE","LU0228659784.USD","LU0417516902.SGD","BK1161","LU2778985437.USD","BK1500","KCE","06821","BK1141","BK1593","601066","01099","09688","06160","IE00B5MMRT66.SGD","SG9999004311.SGD","LU2476274308.USD","IE00B3M56506.USD","LU0828237510.HKD","LU1770034418.SGD","LU2476274720.SGD","BK1197","LU0348825331.USD","01530","LU2399975544.HKD","02268","BK1207","BK1100","HK0000165453.HKD","BK1588","02196","BK1574","LU1969619763.USD","03933","09926","LU0348827113.USD","LU2328871848.SGD","LU0640798160.USD","BK1515","LU1115378108.SGD","BK1583","IE00BPRC5H50.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665645053","title":"复星医药(02196.HK)控股子公司279.96亿印度卢比出售Gland Pharma约6.00%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2665645053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665645053?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:30","pubTimestamp":1788690653,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1191","BK1593","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665517364","title":"复星医药(02196.HK)拟回购不超过10亿港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665517364","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665517364?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:25","pubTimestamp":1788690331,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02196","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195759296","title":"复星医药减持Gland Pharma 6%股权 回笼约279.96亿印度卢比","url":"https://stock-news.laohu8.com/highlight/detail?id=1195759296","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195759296?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:21","pubTimestamp":1788690101,"startTime":"0","endTime":"0","summary":"2026年9月6日，复星医药公布，其控股子公司Fosun Pharma Industrial Pte. Ltd.已于印度时间2026年9月4日通过大宗交易及集中竞价方式出售Gland Pharma Limited9,897,000股，约占截至2026年9月3日Gland Pharma已发行股份总数的6.00%。本次交易总对价为279.96亿印度卢比，折合约2.94亿美元，成交均价（同口径）约为每股2,828.78印度卢比，较前一交易日收盘价2,907.90印度卢比折让约2.72%。交易完成后，复星医药集团仍持有Gland Pharma 75,496,934股，持股比例由51.76%降至45.76%，公司仍为Gland Pharma的控股股东，后者继续纳入集团合并报表范围。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175630514","title":"复星医药拟12个月内回购不超10亿港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1175630514","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175630514?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:21","pubTimestamp":1788690098,"startTime":"0","endTime":"0","summary":"复星医药9月6日公告，为提升公司长期价值并回馈股东，董事会已批准启动“2026年H股回购方案”。根据公告，公司拟自2026年8月27日起12个月内，以不超过10亿港元的资金总额回购H股。此次回购将依据公司于2026年6月16日股东周年大会、H股类别股东会及A股类别股东会授予的H股回购一般性授权执行。复星医药表示，将根据市场情况决定已回购H股的具体用途，包括但不限于注销相关股份或将其作为库存股持有。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364975","title":"复星医药：拟12个月内回购不超过10亿港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364975","media":"南方财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665364975?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:12","pubTimestamp":1788689520,"startTime":"0","endTime":"0","summary":"南财智讯9月6日电，复星医药（02196.HK）发布自愿公告，基于对集团发展前景的信心及内在价值的认可，经董事会批准，公司拟自2026年8月27日起12个月内回购H股，回购资金总额不超过10亿港元。本次回购依据2026年6月16日股东周年大会、H股类别股东会及A股类别股东会授予董事会的H股回购一般性授权实施。回购H股用途包括注销或作为库存股份持有。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609063866106963.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609063866106963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK0175","BK0188","BK0196","BK0239","BK0060","BK1191","BK0028","BK0096","BK1515","BK0183","BK0187","02196","BK0012","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665785361","title":"复星医药最新公告：拟出售GlandPharma部分股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2665785361","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665785361?lang=zh_cn&edition=full","pubTime":"2026-09-06 16:50","pubTimestamp":1788684654,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司复星医药新加坡公司通过大宗交易及集中竞价方式出售989.70万股GlandPharma股份，占其总股本6.00%，交易总对价约2.94亿美元。交易完成后，公司仍持有GlandPharma约45.76%股权，为其控股股东。出售所得将增厚净资产，不计入投资收益。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600007390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","600196","BK0239","02196","BK0196","BK1191","BK0012","BK0188","BK0060","BK0175","BK0096","BK1593","BK0183","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665036541","title":"每周股票复盘：复星医药（600196）H股购回及药品新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2665036541","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665036541?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:16","pubTimestamp":1788632172,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，复星医药报收于22.34元，较上周的22.87元下跌2.32%。本周，复星医药8月31日盘中最高价报22.76元。来自公司公告汇总：芦沃美替尼片新增适应症获国家药监局批准。股本股东变化上海复星医药(集团)股份有限公司于2026年8月31日购回70,500股H股股份，每股价格介乎16.01港元至16.05港元，总代价为1,130,225港元，拟持作库存股份。购回后30日内不得发行新股或出售库存股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600196","BK0239","BK1191","BK0175","BK0183","BK0188","BK1593","02196","BK0187","BK0096","BK0028","BK0060","BK1515","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171429000","title":"复星医药(02196)：控股股东质押3.30亿股A股 占公司总股本12.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171429000","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171429000?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:33","pubTimestamp":1788514387,"startTime":"0","endTime":"0","summary":"2026年9月4日，复星医药公告称，其控股股东上海复星高科技（集团）有限公司于2026年9月3日将持有的3.30亿股公司A股办理质押，质押期限自2026年9月3日至2028年9月8日，质权人为中国工商银行股份有限公司上海市长宁支行，质押资金用于偿还债务。本次质押股份占复星高科技所持公司股份的34.32%，占公司截至2026年9月3日收市总股本的12.36%。截至2026年9月3日收市，复星高科技持有复星医药961,424,455股股份，占公司总股本的36.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152227340","title":"复星医药(02196)：控股子公司8,079万元股东借款续展至2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=1152227340","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152227340?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:32","pubTimestamp":1788514332,"startTime":"0","endTime":"0","summary":"2026年9月4日，上海复星医药（集团）股份有限公司公告称，其控股子公司上海复云健康科技有限公司已与三方股东——复星健康、宁波复技及控股股东上海复星高科技（集团）有限公司于2026年9月3日签署《2026补充协议》，就现有股东借款统一办理续展。根据公告，三方股东此前已向复云健康合计提供8,079万元股东借款。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338732","title":"复星医药(02196.HK)获控股股东复星高科技质押3.3亿股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664338732?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:26","pubTimestamp":1788513984,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02827","BK1147","82846","BK1515","83188","03130","83130","07233","02196","02846","03188","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338252","title":"复星医药：公司始终重视资产质量及财务稳健性","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664338252?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:15","pubTimestamp":1788513345,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药09月04日在投资者关系平台上答复投资者关心的问题。公司重视投资者利益及市场信心，也持续关注投资者及市场对公司经营发展、资产质量及财务结构等方面的反馈，并致力于持续提升经营质量和长期价值创造能力。公司始终重视资产质量及财务稳健性，持续强化资产管理、风险管控及优化资产结构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400030076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0175","BK0028","BK0188","BK1191","BK0183","BK0060","BK0196","BK0239","BK1515","BK1593","BK0012","BK0187","600196","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664840380","title":"复星医药：复星高科技质押3.30亿股用于偿还债务","url":"https://stock-news.laohu8.com/highlight/detail?id=2664840380","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664840380?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:25","pubTimestamp":1788510357,"startTime":"0","endTime":"0","summary":"南财智讯9月4日电，复星医药公告，公司控股股东上海复星高科技(集团)有限公司于2026年9月3日将其持有的330000000股A股股份办理质押，占其所持股份比例34.32%，占公司总股本比例12.36%，质押用途为偿还债务。本次质押后，复星高科技累计质押股份数量为696275000股，占公司总股本26.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609043865437383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609043865437383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK0012","BK0060","BK0183","BK0188","BK0196","BK0096","BK0175","BK1515","BK0239","02196","BK1593","600196","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664870632","title":"复星医药（600196）披露控股子公司药品新增适应症获注册批准，9月3日股价上涨0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664870632","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664870632?lang=zh_cn&edition=full","pubTime":"2026-09-03 22:05","pubTimestamp":1788444327,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，复星医药报收于22.28元，较前一交易日上涨0.36%，最新总市值为594.97亿元。该股当日开盘22.21元，最高22.35元，最低22.11元，成交额达2.77亿元，换手率为0.59%。近日，复星医药发布关于控股子公司药品新增适应症获注册批准的公告。公告显示，公司控股子公司上海复星医药产业发展有限公司的芦沃美替尼片新增适应症获国家药品监督管理局批准，新增适应症为用于伴有症状、无法手术的丛状神经纤维瘤的I型神经纤维瘤病成人患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300042149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0028","BK0188","02196","BK0012","BK0183","BK1593","BK0060","BK0096","BK0175","BK0187","600196","BK0239","BK1515","BK0196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.0714},{"period":"1month","weight":0.0129},{"period":"3month","weight":0.087},{"period":"6month","weight":-0.0861},{"period":"1year","weight":-0.3294},{"period":"ytd","weight":-0.0931}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司通过五个分部开展业务。制药分部主要从事药品的研发、生产和销售。医疗器械与医学诊断分部主要从事医疗器械和诊断产品的研发、生产和销售。医疗健康服务分部主要从事提供医疗健康服务及医院管理。医药分销和零售分部主要从事医药、器械分销和零售。 该公司还运营其他分部。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044495},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036179},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044259},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024935},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.032656},{"month":7,"riseRate":0.642857,"avgChangeRate":0.03393},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.040558},{"month":9,"riseRate":0.5,"avgChangeRate":0.016457},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020365},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034477},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015129}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}